Absci (ABSI) Short-term Investments (2022 - 2026)
Absci (ABSI) posted Short-term Investments of $117.1 million for Q1 2026, down 5.79% sequentially from $124.3 million in Q4 2025, and up 34.59% YoY from $87.0 million in Q1 2025.
Analysis
Absci (ABSI) Short-term Investments (2022 - 2026) Analysis & Trends
Absci has reported Short-term Investments for 5 years, with the latest figure at $117.1 million in Q1 2026.
- Quarterly Short-term Investments rose 34.59% year-over-year to $117.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.1 million (up 34.59% YoY) and the FY2025 annual result came in at $124.3 million, up 74.5% from the prior year.
- Short-term Investments retreated to $117.1 million in Q1 2026 per ABSI's latest filing, from $124.3 million in the prior quarter.
- Over five years, Short-term Investments peaked at $143.0 million in Q3 2025 and troughed at $25.3 million in Q4 2023.
- A 5-year average of $90.7 million and a median of $88.9 million in 2024 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2023 and 2024: Short-term Investments sank 75.79% in 2023, then jumped 181.5% in 2024.
- Over 5 years, Short-term Investments stood at $104.5 million in 2022, then tumbled by 75.79% to $25.3 million in 2023, then surged by 181.5% to $71.2 million in 2024, then soared by 74.5% to $124.3 million in 2025, then fell by 5.79% to $117.1 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $117.1 million, $124.3 million, and $143.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 93.28 Mn |
| Mar 31, 2026 | 117.08 Mn |
| Dec 31, 2025 | 124.27 Mn |
| Sep 30, 2025 | 143.00 Mn |
| Jun 30, 2025 | 79.43 Mn |
| Mar 31, 2025 | 86.99 Mn |
| Dec 31, 2024 | 71.21 Mn |
| Sep 30, 2024 | 88.87 Mn |
| Jun 30, 2024 | 102.31 Mn |
| Mar 31, 2024 | 102.71 Mn |
| Dec 31, 2023 | 25.30 Mn |
| Sep 30, 2023 | 43.75 Mn |
| Jun 30, 2023 | 63.54 Mn |
| Mar 31, 2023 | 132.85 Mn |
| Dec 31, 2022 | 104.48 Mn |
| Sep 30, 2022 | 73.99 Mn |